50,000 weekly increased vitamin D levels in breast cancer patients – Mar 2011

---

The effect of various vitamin D supplementation regimens in breast cancer patients - March 2011

Breast Cancer Res Treat. 2011 Mar 8.
Peppone LJ, Huston AJ, Reid ME, Rosier RN, Zakharia Y, Trump DL, Mustian KM, Janelsins MC, Purnell JQ, Morrow GR.
Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Ave, Box 704, Rochester, NY, 14642, USA, luke_peppone at urmc.rochester.edu.

Vitamin D deficiency in the patients treated for breast cancer is associated with numerous adverse effects (bone loss, arthralgia, and falls).
The first aim of this study was to assess vitamin D status, determined by 25-OH vitamin D levels, among women diagnosed with breast cancer according to demographic/clinical variables and bone mineral density (BMD).

The second aim of this study was to evaluate the effect of daily low-dose and weekly high-dose vitamin D supplementation on 25-OH vitamin D levels.
This retrospective study included 224 women diagnosed with stage 0-III breast cancer who received treatment at the James P. Wilmot Cancer Center at the University of Rochester Medical Center.

Total 25-OH vitamin D levels (D(2) + D(3)) were determined at baseline for all participants.
Vitamin D deficiency was defined as a 25-OH vitamin D level < 20 ng/ml, insufficiency as 20-31 ng/ml, and sufficiency as ?32 ng/ml.

BMD was assessed during the period between 3 months before and 6 months following the baseline vitamin D assessment.

Based on the participants' baseline levels, they received either

• no supplementation,
• low-dose supplementation (1,000 IU/day), or
• high-dose supplementation (?50,000 IU/week),

and 25-OH vitamin D was reassessed in the following 8-16 weeks.

Approximately 66.5% had deficient/insufficient vitamin D levels at baseline.
Deficiency/insufficiency was more common among non-Caucasians, women with later-stage disease, and those who had previously received radiation therapy (P < 0.05).
Breast cancer patients with deficient/insufficient 25-OH vitamin D levels had significantly lower lumbar BMD (P = 0.03).
Compared to the no-supplementation group, weekly high-dose supplementation significantly increased 25-OH vitamin D levels, while daily low-dose supplementation did not significantly increase levels. Vitamin D deficiency and insufficiency were common among women with breast cancer and associated with reduced BMD in the spine.
Clinicians should carefully consider vitamin D supplementation regimens when treating vitamin D deficiency/insufficiency in breast cancer patients.
PDF is attached at the bottom of this page

---

The Effect of Various Vitamin D Supplementation Regimens in Breast Cancer Patients - 2014 (same authors)

Ann Surg Oncol. 2012 Aug; 19(8): 2590–2599. doi: 10.1245/s10434-012-2297-3
Luke J. Peppone, PhD, Alissa J. Huston, MD, Mary E. Reid, PhD, Randy N. Rosier, MD, Yousef Zakharia, Donald L. Trump, MD, Karen M. Mustian, PhD, MPH, Michelle C. Janelsins, PhD, Jason Q. Purnell, PhD, MPH, and Gary R. Morrow, PhD, MS

Purpose
Vitamin D deficiency in patients treated for breast cancer is associated with numerous adverse effects (bone loss, arthralgia, and falls). The first aim of this study was to assess vitamin D status, determined by 25-OH vitamin D levels, among women diagnosed with breast cancer according to demographic/clinical variables and bone mineral density (BMD). The second aim of this study was to evaluate the effect of daily low-dose and weekly high-dose vitamin D supplementation on 25-OH vitamin D levels.

Methods
This retrospective study included 224 women diagnosed with Stage 0-III breast cancer who received treatment at the James P. Wilmot Cancer Center at the University of Rochester Medical Center. Total 25-OH vitamin D levels (D2 + D3) were determined at baseline for all participants. Vitamin D deficiency was defined as a 25-OH vitamin D level < 20 ng/mL, insufficiency as 20-31 ng/mL, and sufficiency as ≥ 32 ng/mL. BMD was assessed during the period between 3 months prior to and 6 months following the baseline vitamin D assessment. Based on the participants’ baseline levels, they received either no supplementation, low-dose supplementation (1,000 IU/day), or high-dose supplementation (≥ 50,000 IU/week), and 25-OH vitamin D was reassessed in the following 8-16 weeks.

Results
Approx 66.5% had deficient/insufficient vitamin D levels at baseline. Deficiency/insufficiency was more common among non-Caucasians, women with later-stage disease, and those who had previously received radiation therapy (p<0.05). Breast cancer patients with deficient/insufficient 25-OH vitamin D levels had significantly lower lumbar BMD (p=0.03). Compared to the no supplementation group, weekly high-dose supplementation significantly increased 25-OH vitamin D levels, while daily low-dose supplementation did not significantly increase levels.

Conclusions
Vitamin D deficiency and insufficiency were common among women with breast cancer and associated with reduced BMD in the spine. Clinicians should carefully consider vitamin D supplementation regimens when treating vitamin D deficiency/insufficiency in breast cancer patients.
 Download the PDF from Vitamin D Life

---

See also Vitamin D Life

• Triple-negative breast cancer is 3X more frequent if less than 32 ng of vitamin D – March 2012 by same author
• All items in Breast Cancer and Vitamin D 240 items
• Overview Cancer and vitamin D which includes a lot on breast cancer

---

There have been 6827 visits to this page